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Abstract Immunotherapy targeting the hTERT subunit
of telomerase has been shown to induce robust immune
responses in cancer patients after vaccination with single
hTERT peptides. Vaccination with dendritic cells (DCs)
transfected with hTERT mRNA has the potential to induce
strong immune responses to multiple hTERT epitopes and
is therefore an attractive approach to more potent immu-
notherapy. Blood samples from such patients provide an
opportunity for identiﬁcation of new, in vivo processed
T-cell epitopes that may be clinically relevant. A 62-year-
old female patient underwent radical surgery for a pan-
creatic adenocarcinoma. After relapse, she obtained stable
disease on gemcitabine treatment. Due to severe neutro-
penia, the chemotherapy was terminated. The patient has
subsequently been treated with autologous DCs loaded
with hTERT mRNA for 3 years. Immunomonitoring was
performed at regular intervals following start of vaccina-
tion and clinical outcome measured by CT and PET/CT
evaluation. The patient developed an immune response
against several hTERT-derived Th and CTL epitopes. She
presently shows no evidence of active disease based on
PET/CT scans. No serious adverse events were experi-
enced and the patient continues to receive regular booster
injections. We here provide evidence for the induction of
hTERT-speciﬁc immune responses following vaccination
of a pancreas cancer patient with DCs loaded with hTERT
mRNA. These responses are associated with complete
remission. A thorough analysis of this patient immune
response has provided a unique opportunity to identify
novel epitopes, associated with clinical effects. These will
be included in future hTERT vaccines.
Keywords Telomerase (hTERT)  Epitope identiﬁcation 
Dendritic cell vaccination  Pancreas cancer
Introduction
Pancreaticadenocarcinomaisrankedfourthasacauseofcancer
death world wide and is regarded as an essentially incurable
disease. Patients with non-resectable, localized disease treated
withchemotherapyhaveamediansurvivalof8–10 months[1].
At best, chemotherapy prolongs survival for a few months.
Thus, new treatment modalities are urgently needed. Immuno-
therapy may represent alternative treatment modalities and are
presently under study in many cancer centres.
The rapid tumour progression followed by deterioration
of the immune system is characteristic for patients with
pancreas cancer. This argues for selection of patients for
immunotherapy, amongst those where an initial stabiliza-
tion of the disease by chemotherapy has been obtained. In
this way, the immune system may have a chance to develop
and consolidate the initial therapeutic response and possi-
bly induce long-term survival beneﬁt.
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in pancreatic cancer have been tested in the clinic [2].
Telomerase (hTERT) is an attractive antigen target appli-
cable also against pancreatic cancer [3]. Moreover, telo-
merase is expressed in cancer stem cells and targeting this
antigen could therefore be an important tool to eliminate
these cells which are not easily killed by conventional
therapy [4].
The most widely used approach for the identiﬁcation of
novel tumour antigen targets is reverse immunology where
epitopes are predicted in silico and then validated experi-
mentally [5]. The concept is rational, but remains a cum-
bersome and complex process where approximately 50% of
candidate peptides are lost at every step after selection of a
target sequence. This approach may also lead to the identi-
ﬁcation of target peptides that may not be the most relevant
inaclinicalsetting.Lessthan1%ofthepeptidesencodedby
a target sequence are estimated to be antigenic, immuno-
genic,processedandpresentedonthecellsurfaceandableto
inducespeciﬁctumourlysis.Wehaveherebeenabletousea
direct approach immunising the patient with full-length
hTERT mRNA and identifying the hTERT peptides capable
of inducing patient T-cell responses post-vaccination.
Vaccination with mRNA-transfected DCs also offers the
advantage of generating T-cell responses against multiple
epitopes, involving both the CD4? Th and CD8? T-cell
subsets. In the human system, DCs transfected with mRNA
have previously been shown to induce CTL responses to
hTERT in vitro [6]. Employed as treatment against meta-
static prostate cancer, Su et al. also demonstrated successful
generation of hTERT-speciﬁc T-cell responses measured as
interferon-c (IFN-c) secreting CD8? T cells and CTL-
mediated killing of hTERT-positive targets [7]. Four
patients experienced partial clinical responses. However, no
hTERT epitopes were characterized in these studies.
Here, we have characterized the hTERT epitopes rec-
ognized by the patient T cells following vaccination with
hTERT-transfected DCs. Vaccination resulted in a diverse
immune response involving both CD4? Th cells and
CD8? T cells. This hTERT-speciﬁc T-cell response may
be responsible for the effects such as the tumour regression
and long-term survival observed. This opens up new ave-




A 62-year-old woman received surgery for a ductal ade-
nocarcinoma of the pancreas. About 10 months later, she
developed multiple metastatic lymph node lesions in the
abdomen. She was treated with standard gemcitabine
chemotherapy for 5 months and obtained stable disease on
this treatment. The chemotherapy was cancelled due to
severe neutropenia despite a 50% dose reduction. She was
then vaccinated with DCs loaded with hTERT mRNA on a
compassionate use basis following a standard clinical
protocol used for patients with malignant melanoma. This
protocol had been approved by the Norwegian Medicinal
Authorities (SLV) and the regional ethical committee
(REK). The patient had given informed consent and the
treatment was performed according to the World Medical
Association Declaration of Helsinki.
Production of mRNA-transfected DCs
DCs were generated as described earlier [8]. Brieﬂy,
monocytes obtained from leukapheresis product were
cultured for 5 days with granulocyte–macrophage colony-
stimulating factor (GM-CSF) and interleukin-4 (IL-4) and
then cultured for 2 days with cytokines facilitating matu-
ration (interleukin-1 b (IL-1b), interleukin-6 (IL-6), tumour
necrosis factor a (TNF-a) and prostaglandin E2 (PGE2).
The resulting mature DCs were transfected (tDCs) with
hTERT mRNA by square wave electroporation. As a
control, a fraction of the DCs was mock transfected (no
mRNA). The mature DC phenotype was evaluated by ﬂow
cytometry and shown to have high levels of HLA class II,
CD86 and CD83, but not CD14. The DC viability was
[85%, as assessed by trypan blue staining.
Fast DCs were generated for the second and third vac-
cine batches [9–11]. In brief, monocytes were cultured for
2 days with GM-CSF and IL-4 and then matured for 1 day
in the same way as for conventional DC before electro-
poration. The DCs were then left overnight in the incubator
prior to cryopreservation.
Vaccine
The vaccine consisted of 5 9 10
6 autologous monocyte-
derived dendritic cells electroporated with hTERT mRNA.
The patient received 4 weekly intradermal injections the
ﬁrst month followed by monthly booster injections. The
ﬁrst vaccine batch consisted of 5 9 10
6 conventional DCs
and the patient had 15 vaccines administered. Batches 2
and 3 consisted of 10 and 17 vaccines, respectively, each
containing 5 9 10
6 hTERT mRNA loaded fast DCs.
Clinical monitoring
Adverse events were recorded and graded according to the
NCI common toxicity criteria, as previously reported [8].
Only minor side effects were observed, with no treatment-
relatedgradeIII–IVtoxicity.Objectivetumourresponsewas
810 Cancer Immunol Immunother (2011) 60:809–818
123assessedbyclinicalexaminationandCTscanspriortostartof
vaccination and every 3 months during the vaccination. The
tumour response was classiﬁed according to the Response
Evaluation Criteria in Solid Tumours (RECIST) [12].
Immunomonitoring
Peripheral blood mononuclear cells (PBMCs) were
obtained prior to the four standard vaccinations, after
5 weeks, after 12 weeks and before each monthly booster
vaccination thereafter. The PBMCs were isolated and fro-
zen as previously described [8]. Thawed PBMCs were
stimulated once in vitro with tDCs, cultured and then tested
in triplicates in T-cell proliferation assays (
3H-Thymidine)
as previously described [8]. Antigen-presenting cells
(APCs) were irradiated tDCs and mock DC controls.
PBMCs from various time points were stimulated with an
overlapping hTERT 15-mer peptide library or a 30-mer
hTERT peptide (within the hTERT amino acid sequence
563–735, GenBank accession number: AB085628) and
then tested in proliferation assays as above using irradiated
PBMCs as APCs as already described [3]. All peptides
were purchased from ProImmune (Oxford, UK). Stimula-
tory index (SI) is deﬁned as proliferation with peptide
divided by proliferation without peptide. SI C 2 is con-
sidered a positive response.
Flow cytometry
Pentamer staining was performed on fresh or frozen patient
PBMCs. Phycoerythrin (PE)-conjugated pentamers were
manufactured by ProImmune. Pentamer with HIV peptide
SLYNTVATL-A*0201 was used as a negative control.
Cells were stained with pentamers for 10 min at room
temperature (RT), washed in staining buffer consisting of
phosphate-buffered saline (PBS) containing 0.1% human
serum albumin (HSA) and 0.1% sodium azide before
staining with anti-CD4-ﬂuorescein isothiocyanate (FITC),
anti-CD19-FITC, anti-CD8-peridinin chlorophyll protein
complex (PerCP) and anti-CD3-Paciﬁc Blue (PB) (all from
eBioscience San Diego, USA). FITC was used as a dump
channel to exclude all CD4? and CD19? cells from the
analysis. For intracellular staining, 12-day peptide-stimu-
lated T cells were stimulated overnight in the presence of
Brefeldin A (BD Bioscience, NJ, USA) at 10 lg/ml and BD
Golgistop (BD Biosciences) at a 1/1,000 dilution with an
autologous Epstein Barr Virus–transformed B-lymphoblas-
toidcelllines(EBV-LCL)loadedwithpeptideataTcell-to-
target ratio of 5:1. Non-peptide-loaded target cells and T
cells alone were used as negative controls. Cells were then
stainedforCD4-PE-Cy7,CD8-PB,interferon-gamma(IFN-c)-
FITC (eBioscience), interleukin-2 (IL-2)-allophycocyanin
(APC) (eBioscience) and tumour necrosis factor-alpha
(TNF-a)-PE (BD Bioscience) using the BD Cytoﬁx/Cyto-
perm kit according to the manufacturer’s instructions (BD
Bioscience). Finally, cells were resuspended in staining
buffer containing 1% paraformaldehyde. All antibodies and
reagents for intracellular cytokine staining were purchased
from BD Bioscience except where noted. Fifty to one
hundred thousand CD8? T cells were acquired per sample
for the detection of pentamer-positive populations using a
BD LSR II ﬂow cytometer and the data were analysed
using FlowJo software (Treestar Inc., Ashland, OR, USA).
IFN-c ELISPOT
The IFN-c ELISPOT assays were performed essentially as
previously described [13]. Responder T cells were seeded
in triplicates at 0.1 9 10
6 T cells/well and stimulated with
irradiated, autologous PBMCs at a E:T ratio of 2:1. Long
peptides (30- and 15 mers) 660–689, 663–677 and 673–687
were added at 25 uM and 10 mer peptide 674–683 10 uM.
Negative controls with T cells only and positive controls
stimulated with SEC-3 were included. Spots were enu-
merated using an automated analyzer, CTL IMMUNO-
SPOT S5 VERSA-02-9030 (Cellular Technology Ltd,
Shaker Heights, USA).
Results
Clinical development and response
Following radical surgery and relapse, the patient experi-
enced disease stabilization on gemcitabine treatment, but
after 5 months the chemotherapy treatment was suspended
due to adverse effects, neutropenia grade 2 (1.0 9 10
9/l),
despite a dose reduction of 50%. She was then offered DC
vaccination as an alternative treatment as described in the
timeline (Fig. 1). She experienced a marked decrease in
lymph node metastases ([30%, partial response) as shown
on CT scans obtained after 32 months of vaccination
(Fig. 2a–c). Furthermore, there was no uptake on repeated
Fig. 1 Timeline for the clinical development of the pancreatic cancer
patient treated with DC vaccine
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123PET/CT scans indicating that the lesions have no increased
metabolic activity compared to other lymph nodes. The
patient has not experienced any serious treatment-related
side effects during the 3-year vaccination period. Due to
the demonstration of an immune response against the ﬁrst
DC vaccine batch and the presence of stable disease, new
vaccine batches of fast DC were produced and immuno-
monitoring continued.
hTERT-speciﬁc T-cell proliferation
A proliferative T-cell response to the DC vaccine could be
measured in vitro 3 months post-vaccination and was
found stable from month 6 (data not shown). Having
documented the presence of an immune response to
hTERT-transfected DCs, we wanted to investigate which
hTERT epitopes were responsible for inducing the immune
response. This was tested by measuring T-cell proliferation
against an hTERT peptide library (Fig. 3) and ex vivo
pentamer staining of PBMCs. We detected proliferative
T-cell responses (SI C 2) against eight of the 15-mer
hTERT peptides from the overlapping peptide library and a
30-mer hTERT peptide at different time points throughout
the vaccination period. The 30-mer peptide 660–689 was
tested at later time points since it was synthesized after
testing had started. Figure 3 shows a summary of the
strongest responses detected against nine different peptides
at various time points post-vaccination. The kinetics of the
proliferative T-cell responses against these nine peptides is
presented in Table 1 with the ﬁrst responses being detect-
able at 9 months after the start of vaccination. Importantly,
all peptide-speciﬁc T-cell responses could be detected only
post-vaccination, as shown graphically for four represen-
tative peptides in Fig. 4. Responses against most of these
peptides became detectable in vitro only after several
months of vaccination. This demonstrates the presence of
hTERT-speciﬁc T-cell responses after vaccination and that
some of these responses required repeated vaccination to
develop to detectable levels.
Pentamer analysis of hTERT peptide–speciﬁc T cells
The ability of the vaccine to induce CD8? T cells speciﬁc
for HLA-A*0201 restricted hTERT peptides was assessed
by ex vivo hTERT pentamer analysis of PBMCs harvested
at different time points. A representative example of
hTERT pentamer analysis from pre- and post-vaccination
is shown in Fig. 5a. The top panel shows the presence
of hTERT pentamer–positive populations of 0.12% of
the CD8? T cells for both the 10-mer peptide 674–683
pentamer and the 9-mer peptide 653–661 pentamer
pre-vaccination. In the bottom panel at 24 months
Fig. 2 CT pictures showing
lymph node enlargement. a at
the time of relapse before start
of chemotherapy in November
2006 (22.6 mm), b at time of
discontinued chemotherapy
treatment in April 2007
(26.3 mm) and c after DC
vaccination in February 2010
(15.9 mm)
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the 674–683 pentamer, whereas 0.13% bind the 653–661
pentamer. These results together with the hTERT pentamer
analysis at several other time points throughout the vacci-
nation period (Fig. 5b), including a third hTERT pentamer
(615–624), indicate that the CD8? T cells speciﬁc for the
674–683 epitope expanded the most after vaccination. Pen-
tamer-positive T cells were also detected pre-vaccination
with increased frequencies for the 674–683 peptide at
months 11, 17, 24, 30 and 32. The 674–683-speciﬁc T-cell
population could be further increased to approximately 3%
of CD8? T cells after in vitro peptide stimulation (data not
shown). The 674–683 epitope is part of the hTERT 30-mer
peptide 660–689 which induced strong proliferative T-cell
responses. The 653–661 epitope is embedded in the 15-mer
sequence 651–665 shown not to induce detectable prolifer-
ative responses in Fig. 3. For peptide 653–661, the fre-
quencies were much lower and only very slight increases
Fig. 3 Summary of hTERT-
speciﬁc T-cell responses
detected. T-cell proliferation
against 24 overlapping hTERT
15-mer peptides were tested in




hTERT peptides were detected.
Proliferation was measured in
response to peptide-loaded and
non-loaded autologous PBMC
and a stimulation index of[2
considered an immune response.
Peptide sequences are shown on
the x-axis. Black bars show
peptides inducing T-cell
responses and hatched bars
peptides not inducing responses
Table 1 Kinetics of peptide-speciﬁc T-cell proliferation at all time points tested
Time point hTERT peptides
613–627 633–647 663–677 673–687 578–592 691–705 705–719 627–641 660–689
Baseline 0.8
a 0.8 0.6 0.6 0.8 0.7 0.6 0.7 nt
1 week 0.5 0.8 0.6 0.6 0.5 0.6 0.6 0.6 nt
6 weeks 0.7 0.9 0.8 0.8 0.7 1 0.6 1 nt
3 months 1 1 0.8 0.8 1 0.7 0.8 0.7 nt
4 months 1.4 1 1 1 1.4 1.4 0.7 1.4 nt
5 months 0.9 0.7 1 1 0.9 1 0.4 1 nt
6 months 1.4 1.2 1.5 1.5 1.4 1.2 0.6 1.2 nt
9 months 2.1 0.8 0.7 1 2.7 1.3 1.1 1 nt
17 months nt nt 3.0 3.5 nt 2.5 nt 2.2 nt
18 months nt nt nt nt nt nt nt nt 3.1
19 months nt nt nt nt nt nt nt nt 2.1
21 months nt nt 1 1 nt 1.5 nt 0.5 nt
22 months nt nt 1.2 1 nt 1.2 nt 0.9 nt
23 months nt nt 1 0.9 nt 1 nt 1.2 nt
24 months 0.8 11.6 0.8 1.1 1.1 1.5 2.5 5.9 2.97
30 months nt nt 1.3 13.3 nt nt nt nt 17.1
nt non-tested
a Proliferation is expressed as stimulation index (SI)
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123were detected at months 17, 29, 30 and 32. Increased fre-
quencies of T cells speciﬁc for the peptide 615–624 could in
addition be detected at months 30 and 32 with 0.45% and
0.2% of the CD8? T cells being positive, respectively.
Cytokine secretion by hTERT peptide–speciﬁc T cells
After one round of in vitro stimulation of PBMCs with the
30-mer hTERT peptide 660–689 containing at least two
T-helper epitopes (663–677 and 673–687) as well as the
CTL epitope in the 674–683 pentamer, we could detect a
population of multifunctional CD4? T cells with a Th1-
type proﬁle. These cells secreted IFN-c, IL-2 and TNF-a
when cultured overnight with autologous Epstein Barr
Virus (EBV)-transformed B cells loaded with the same
peptide (Fig. 6a). There was no increase in cytokine pro-
duction in the CD8? T-cell population after stimulation
with the peptide-loaded target cells compared to those
stimulated with non-peptide-loaded targets (data not
shown). High background levels of IL-2 observed may be
due to the 12-day culture and to some stimulation given by
the transformed B cell line which could express hTERT.
hTERT peptide–speciﬁc IFN-c secretion was also detected
by ELISPOT upon restimulation with 660–689 and nested
epitope 673–687 after 12-day cultures with hTERT 30-mer
peptide (shown at 30 months in Fig. 6b). Here, the CD4?
and CD8? T-cell responses were not separated, but the
CTL epitope did not induce IFN- c secretion much above
the background level. Taken together, these data conﬁrm
that T-cell populations speciﬁc for multiple hTERT pep-
tides have been induced after vaccination of this patient.
Discussion
In this paper, we describe a pancreas cancer patient with an
extraordinary disease course following treatment with
chemotherapy and vaccination with autologous DC trans-
fected with hTERT mRNA. In addition, we demonstrate
how vaccination with full-length mRNA can be used for
the discovery of novel, clinically validated T-cell epitopes.
The patient underwent radical surgery in January 2006.
Due to post-operative complications, she did not receive
adjuvant chemotherapy. The patient relapsed in November
2006 with enlarged lymph nodes localized in liver hilus,
truncus iliacus and retroperitoneum as assessed by CT. The
original diagnosis was conﬁrmed by re-examination of the
surgical specimen by an independent pathologist. The
patient obtained stable disease on gemcitabine chemo-
therapy that was discontinued due to side effects. In this
clinical setting, from June 2007, the patient has been vac-
cinated with autologous DC loaded with hTERT mRNA on
a compassionate use basis in order to consolidate the
beneﬁcial effect of the chemotherapy.
Rather than developing progressive disease after ended
chemotherapy, the patient experienced a partial response
against the tumour. Two consecutive PET scans in March
and September 2009 revealed no metabolically active
lesions. These intriguing ﬁndings indicate that the immu-
notherapeutic strategy used has induced a clinically rele-
vant immune response in this patient. It was therefore
important to document and study in depth the immune
response against hTERT. Furthermore, as there is a com-
plete lack of information regarding the detailed immune
Fig. 4 Representative pre- and post-vaccination T-cell responses
against hTERT peptides. T-cell responses against selected peptides
throughout the vaccination schedule. Non-peptide-loaded PBMCs
were used as negative controls. W weeks and M months post-start of
vaccination. Flat grey squares represent time points where T-cell
responses against the peptide were not tested. Black bars represent
responses against peptide 660–689, light hatched bars against peptide
627–641, more intense hatched bars against peptide 673–687 and
grey hatched bars against peptide 643–647
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hTERT mRNA for vaccination [7], it was important to
identify hTERT epitopes potentially relevant in the anti-
tumour response for the development of the next genera-
tion of hTERT vaccines.
We found high frequencies of CD8? T-cell-binding
pentamers with new CTL epitopes 674–683, but not
653–661 after vaccination. These two epitopes were HLA-
A*0201 restricted and have not been previously described.
Interestingly, the 9-mer epitope 674–683 is embedded
in a 15-mer peptide 673–687 nearly identical to the R672
Th epitope previously described by Schroers et al. [14].
Importantly, the same 15-mer peptide, 673–687, was also
recognized by the T cells in proliferation assays, indicating
that this region of the hTERT sequence may have elicited
both a CD4? and a CD8? T-cell response in this patient.
Moreover, seven other 15-mer peptides as well as one
30-mer peptide were recognized by T cells from this
patient. Three of these peptides (663–677, 578–592 and
691–705) have not previously been reported. No immune
responses against this set of peptides were observed when
blood samples from six healthy donors were tested in the
same assay (data not presented).
The amount of T-cell proliferation against these peptides
was very variable. It is our general observation that
immune responses against cancer vaccines in patients with
concomitant tumours, as measured in peripheral blood,
ﬂuctuate considerably. This may reﬂect activated tumour-
speciﬁc T cells leaving the blood stream to inﬁltrate the
tumour. Stable immune responses are typically seen in
Fig. 5 Pentamer analysis of
hTERT-speciﬁc HLA-A*0201
restricted CD8? T cells in
peripheral blood. PBMC were
stained directly after isolation
without prior antigen
stimulation. CD4? and CD19?
cells were excluded from the
analysis and plots show
pentamer staining in CD8?
CD3? cells. HIV-pentamer is
used as a negative control for
non-speciﬁc staining.
a Pentamer staining for two
novel hTERT peptides 674–683
and 653–661 is shown. The top
panel shows pentamer analysis
pre-vaccination and the bottom
panel at 24 months after start of
vaccination. b Kinetics of the
frequency of pentamer-positive
cells detected in PBMCs at
different post-vaccination time
points (M = months). Dark






light dotted bars 615–624
pentamer-positive cells,
respectively. At least 50,000
CD8? T cells were acquired
and analysed in each test
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123patients where complete responses have been obtained.
Induction of new hTERT-speciﬁc T cells by repeated
booster vaccinations will contribute to the dynamic
immune response. Taken together, these results demon-
strate that the vaccine has induced T-cell responses against
at least 10 different hTERT epitopes in this patient. The
number of epitopes may be considerably greater as we have
used only a limited number of peptides from an overlap-
ping peptide library not covering the whole sequence as
well as only a few pentamers limited to HLA-A*0201
presented peptides.
There is increasing emphasis on the pivotal role of
CD4? T cell in the anti-tumour response both in sup-
porting CD8? T-cell responses and for their direct anti-
tumour effects [15–18]. The observation of a CD4? T-cell
response against the 660–689 peptide, together with pro-
liferative responses against several other peptides shown
to be recognized by Th clones (Inderberg Suso et al.,
unpublished), in addition to CTL responses against several
HLA-A*0201 restricted epitopes, supports the notion that a
combination of T-helper (Th) and CTL epitopes should be
used in future vaccination protocols. For this reason, the
use of synthetic long peptides (SLP) in cancer vaccination
is very promising. SLPs efﬁciently deliver antigen to DCs
and are processed into both Th and CTL epitopes present in
the peptide. The peptide presentation of SLPs which
require internalization and intracellular processing has
been shown to be prolonged compared to direct exogenous
MHC class I molecule loading and presentation of short
peptide not requiring processing [19]. The prolonged
Fig. 6 CD4? T-cell cytokine
secretion upon stimulation with
a hTERT 30-mer peptide
660–689. PBMCs were cultured




proliferative responses. a The
T-cell lines obtained from blood
samples harvested 26 months
post-vaccination start were
restimulated overnight with
autologous EBV-LCL loaded or
not with peptide prior to
intracellular cytokine staining.
T cells were stained with
CD4-PE-Cy7 or CD8-PB and
IFN-c-FITC, IL-2-APC and
TNF-a-PE. Plots show cells
gated on CD4? T cells.
b Frequency of peptide-speciﬁc
IFN-c secretion detected in
ELISPOT assays from month 30
after start of vaccination.
Autologous PBMCs were used
as target cells. The E:T ratio
was 2:1. Responses against
peptides 663–667, 673–687,
660–689 and 674–683 were
tested
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123peptide presentation is particularly important if the T-cell
epitope displays weak MHC class I binding.
In addition, vaccination with short peptides can lead to
tolerance of the immunizing antigens rather than immunity
unless ex vivo loading of DC is used [20, 21]. Vaccinating
with both CTL and Th epitopes has been shown to prevent
this tolerance induction and the immunogenicity is further
improved if these are included in one single hybrid peptide
[22, 23]. This could provide an explanation for the strong
immune responses and some of the extraordinary clinical
responses seen in cancer patients vaccinated with GV1001,
a 16-mer hTERT peptide [3, 24]. This Th epitope also
incorporates HLA-A2- and HLA-B7-binding peptide
motifs, and the strength of CD4? T-cell responses detected
against the GV1001 peptide correlates well with patient
survival. Vaccination with full-length mRNA encoding
deﬁned antigens will also induce immune responses to both
T-helper and CTL epitopes as demonstrated by the results
obtained here.
Vaccination in advanced stage cancer patients will often
have limited therapeutic effect by itself due to a combi-
nation of increasing immune suppression and rapidly
growing tumour. The therapeutic effect may be enhanced
when used in conjunction with conventional chemotherapy
or radiotherapy, which may affect both regulatory T cells
and tumour growth. Prior to the start of vaccination, the
patient described here was treated with gemcitabine which
may contribute to the induction of a broader immune
response as shown by Nowak et al. [25]. Furthermore, our
observations indicate that there is no widespread tolerance
against hTERT peptides and that the vaccination strategy
using hTERT mRNA–transfected DCs is highly potent.
Interestingly, despite the presence of a complex hTERT-
speciﬁc immune response over a period of [3 years, no
evidence of autoimmunity involving hTERT-positive nor-
mal cells, such as haematopoietic stem cells, was observed.
This is in line with previous observations in patients with
long-term immune responses following hTERT peptide
vaccination [24] and animal experiments [26]. Our newly
identiﬁed peptides add to the list of 26 hTERT peptides that
have been shown to induce efﬁcient immune responses
against hTERT-positive tumour cells (reviewed in [27]).
We have also demonstrated that CD4? T cells from this
patient, capable of recognizing a 30-mer hTERT peptide
(660–689) encompassing two of the 15-mer and one 9-mer
peptide, produce three Th1-associated cytokines simulta-
neously. This kind of multifunctionality has previously
been demonstrated to give better protection against infec-
tion [28]. Peptide-speciﬁc cytokine secretion from CD8? T
cells could not be detected by ﬂow cytometry and may
reﬂect low initial precursor frequency of this CD8? T-cell
population. This difference in CD4? and CD8? T-cell
numbers could be further increased by a much stronger
proliferation of the CD4? T cells recognizing the Th epi-
topes from the 30-mer peptide than of CD8? T cells in the
12-day culture. The IFN-c ELISPOT conﬁrmed that cyto-
kine secretion occurred mainly in response to Th epitopes.
In conclusion, these results illustrate the feasibility of
vaccination with DCs loaded with mRNA encoding a
deﬁned antigen for the identiﬁcation of immunogenic
T-cell epitopes. The major advantage is that the identiﬁed
epitopes have been processed and presented in vivo and
therefore are potentially clinically relevant. In general, this
type of vaccination provides an opportunity for direct and
fast discovery of novel T-cell epitopes from any tumour-
speciﬁc or tumour-associated antigen.
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